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MBC Patients’ survival over time
Median survival increases over time, but is still measured in months
This is not yet a chronic disease
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•Etirinotecan pegol (NKTR-102) 
Eribulin Inhibits Microtubule Dynamics















3. Generation of nonproductive 
tubulin aggregates
2. No measurable effect on 
shortening (at relevant 
concentrations)
Adapted from Jordan MA et al. Mol Cancer Ther 2005; 4:1086-1095.  
Eribulin Blocks Microtubule Growth by





Eribulin binds to (+) 
ends
Vinblastine binds to (+) 
ends and along sides

















Overall survival by receptor status
nab Paclitaxel
•Paclitaxel bound to albumin in a 
nanoparticle
• Increases drug selectivity for tumor cells 
(albumin intake mechanisms)
•No routine steroid or antihistamine 
premedication required, no toxic 
solvents
Gradishar W et al. J Clin Oncol. 2005;23:7794-7803
Nab-paclitaxel: Proposed mechanism of action
Nab-paclitaxel 
Tumour cells
Desai. Drug Delivery Report 2007/8:16th Ed, 37-41; Desai et al. CCR 2006;12:1317-24

Phase III Trial







Overall Response Rate 33% 19% .001
Time to Progression     23.0 wk 16.9 wk .006
Grade 4 Neutropenia 9% 22% <.001
Grade 3 Sensory Neuropathy 10%* 2% <.001
Albumin-bound paclitaxel: 260 mg/m2 q3w; Paclitaxel:175 mg/m2 q3w
* Median time to improvement: 22 days
Gradishar W et al. J Clin Oncol. 2005;23:7794-7803
Approval/indication in Europe
Based on the results of the Phase III study, nab-paclitaxel 
received EMA approval at a dose of 260 mg/m2 Q3W for the 
treatment of  MBC in adult patients who have failed 1st-line 
treatment for metastatic disease and for whom standard, 
anthracycline-containing therapy is not indicated
Gradishar W et al. JCO 2005;23:7794-803 















(A: n = 76)
100 mg/m2
QW 3/4
(B: n = 76)
150 mg/m2
QW 3/4





















Randomized Phase II study: Nab-paclitaxel Q3W 
vs QW vs docetaxel in 1st-line MBC
A vs B; p=0.024
A vs C; p=0.002
B vs C; NS 
P values are for investigator assessment
Investigator assessment
Independent assessment
Gradishar W et al. JCO 2009;27:3611-9
Randomized Phase II study: OS
*3 degrees of freedom test for overall difference








































300 mg/m2 Q3W 27.7 –
B. Nab-paclitaxel 
100 mg/m2 QW 3/4 22.2 –
C. Nab-paclitaxel 
150 mg/m2 QW 3/4 33.8 HR 0.688
D. Docetaxel
100 mg/m2 Q3W 26.6 –
C vs B: p=0.008; HR 0.575
Nab-paclitaxel improves OS vs traditional taxanes in 
patients with poor prognostic factors*
O’Shaughnessy et al BCRT 2013, April 6 [epub ahead of print]  
Nab-paclitaxel 260 mg/m2 Q3W
Conventional paclitaxel 175 mg/m2 Q3W
Nab-paclitaxel 300 mg/m2 Q3W (A)
Nab-paclitaxel 100 mg/m2 QW 3/4 (B)
Nab-paclitaxel 150 mg/m2 QW 3/4 (C)
Docetaxel 100 mg/m2 Q3W (D)


























Key ongoing trials evaluating nab-paclitaxel in 
breast cancer
Setting Study ID Description No of pt
1st line MBC SNAP
NCT01746225
Randomized phase II study evaluating different nab-paclitaxel 
schedules in patients with HER2-/HR- (or + resistant) MBC
240
1st line MBC tnAcity
NCT01881230
Randomized phase II/III study evaluating nab-paclitaxel + gem or 
carb vs gem + carb in patients with TNMBC




Randomized phase III trial comparing nab-paclitaxel with solvent-
based paclitaxel as part of neoadjuvant chemotherapy for patients 




Phase II, open-label, non-randomized study of nab-paclitaxel for 





Randomized phase III trial comparing nab-paclitaxel with solvent-
based paclitaxel as part of neoadjuvant chemotherapy for patients 






Adjuvant Dynamic marker-Adjusted Personalized Therapy trial 





Phase III trial to compare intense dose-dense adjuvant treatment 
with EnPC to dose-dense, tailored therapy with dtEC-dtD for patients 




A randomized Phase II study of EC/CMF vs nab-paclitaxel plus 
capecitabine as adjuvant chemotherapy for elderly patients with an 
increased risk for relapse of a primary carcinoma of the breast
1458
www.clinicaltrials.gov
Longer first-line chemotherapy duration:
Substantially longer PFS  (HR:0.64)
Gennari et al. J Clin Oncol,2011,29:2144-2149 
Longer first-line chemotherapy duration:
Marginal effect on overall survival  (HR:0.91)
Gennari et al. J Clin Oncol,2011,29:2144-2149 
STUDY SCHEMA  















3 cycles (28-day)  
nab-Paclitaxel 150 mg/m
2
 days 1, 15 
nab-Paclitaxel 100 mg/m
2
 days 1,8,15 
nab-Paclitaxel 75 mg/m
2








First line chemotherapy for metastatic breast 
cancer
In case of toxicity, dose reductions and delays 
are preferred to dose discontinuation
Induction Chemotherapy Maintenance Chemotherapy
SNAP Accrual and Study Duration
• Target Accrual: 240 patients
– (Arm A: 80, Arm B: 80, Arm C: 80)
– 88% power if median PFS of any arm is at 
least 10 mos. compared with reference 7 mos.  
• Study Duration
– Randomization during 30 months
– Additional 12 months of follow-up after the 
last patient entered
• BIG Supporter Trial:  IBCSG 
(coordinating), SOLTI, ICORG, EORTC
tnAcity: Study design





125 mg/m2  + 







Continue treatment until PD or 
unacceptable toxicity
Carboplatin AUC2 + 
gemcitabine 
1000 mg/m2 QW 2/3 
(n=275)
Nab-paclitaxel 
125 mg/m2  + 
gemcitabine 
1000 mg/m2 QW 2/3 
(n=80)
Carboplatin AUC2 + 
gemcitabine 
1000 mg/m2 QW 2/3 
(n=80)
Phase II Phase III
R
1:1
Patients in Phase II 
will not be included 
in Phase III analysis    
US chair: Denise Yardley 
EU co-chair: Nadia Harbeck 
Phase II Study start: June 2013
Phase II estimated completion (primary analysis): June 2015




















• NKTR-102  is the first long-acting topoisomerase I-inhibitor
• Targets tumor tissue through Enhanced Permeability and Retention
(EPR) effect
• Optimized pharmacokinetic profile with continuous tumor  exposure 
but with reduced peak exposures














NKTR-102’s design results in a lower
initial peak concentration of active
topoisomerase I-inhibitor in the blood
33
Phase 2 Study Design:
Randomized to 2 Schedules of NKTR-102
• Primary Efficacy Objective:
— Determine the objective response rate (ORR) by RECIST v 1.0
— Determine the optimal schedule of NKTR-102 in breast cancer











Statistical Hypotheses:  
H0 ORR (RECIST version 1.0) ≤ 5% and Ha ORR ≥ 20%. (Type 1 error = 0.029; type 2 error = 0.145)
Demographics in Phase 2 Study
35
*Out of women only (n=34).
ECOG PS; Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; 
HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.






Age, median yr (range) 53 (33-83) 56 (37-77)
Women, No. (%) 34 (97) 35 (100)




















Postmenopausal, No. (%) 24 (71)* 29 (83)
Time from initial diagnosis to first dose, median yr (range) 4 (0-15) 5.4 (1-19)














Visceral disease 28 (80) 32 (91)
Awada A, et al. Lancet Oncol. 2013;14:1216-1225
Demographics in Phase 2 Study (cont.)
36









Previous cytotoxic regimens in metastatic setting, median No.(range) 1 (0-3) 2 (0-2)
Any previous cytotoxic regimens in the metastatic setting, No. (%)
1 previous cytotoxic regimen













Previous cytotoxic (neo)adjuvant therapy
Previous adjuvant anthracycline
Previous adjuvant taxane



















Awada A, et al. Lancet Oncol. 2013;14:1216-1225
NKTR-102:
Metastatic Breast Cancer Phase 2 Final Results
• Single-agent NKTR-102 demonstrated a 29% ORR in heavily 
pretreated (median 2 prior lines of therapy) advanced metastatic
breast cancer 
— PFS: 4.7 months
— Median OS:  10.3 months
— Progression-free at 6 months:  35.5%
• ORR was maintained in heavily pretreated and poor prognosis 
subsets
— A/T/C pre-treated:  33%
— Triple negative:  33% 
— Visceral disease:  30%  
• Activity in the 3 main subtypes: TNBC, HER2+, Hormone+
37
NKTR-102:
Metastatic Breast Cancer Phase 2 Final Results
• Most common Grade 3/4 toxicity was diarrhea (21%) 
— Typically occurring after approximately 3 months of therapy for both 
schedules
• 21-day schedule better tolerated and more efficacious
— ORR: 29%;  PFS: 5.6 months, OS: 13.1 months 
— Selected for Phase 3 BEACON study
38
Summary of Treatment-emergent Adverse 
Events (TEAEs)








All Grades Grade 3–4 All Grades Grade 3–4
Diarrhea 24 (69) 7 (20) 22 (77) 8 (23)
Nausea 25 (71) 2 (6) 26 (74) 1 (3)
Fatigue 15 (43) 5 (14) 18 (51) 3 (9)
Vomiting 19 (54) 3 (9) 14 (40) 2 (6)
Decreased appetite 14 (40) 1 (3) 12 (34) 0
Constipation 14 (40) 0 9 (26) 0
Abdominal pain 7 (20) 1 (3) 8 (23) 0
Blurred vision 9 (26) 0 6 (17) 0
Dehydration 7 (20) 3 (9) 6 (17) 4 (11)
Neutropenia 6 (17) 4 (12) 7 (20) 4 (11)
Alopecia 7 (20) 0 4 (11) 0
Anemia 6 (17) 1 (3) 4 (11) 1 (3)
Decreased weight 3 (9) 0 7 (20) 0
Dyspnea 6 (17) 1 (3) 3 (9) 0
39Awada A, et al. Lancet Oncol. 2013;14:1216-1225.
• 2 possible treatment-related deaths occurred (both in q14 day): sepsis and acute renal failure following diarrhea. 
NKTR-102:
New Mechanism of Action in Metastatic Breast Cancer
• Most therapies used in MBC 
disrupt microtubules and have 
overlapping toxicities
• In Phase 2, NKTR-102 had activity 
as single agent in breast cancer 
patients with poor prognosis
— Primary toxicity is diarrhea
— Low rates of neutropenia
— No neuropathy
— Little alopecia
— No cardiac toxicity
40





and Resistance with 
Existing Treatments
l i i i i
i i
i i
Currently no other topoisomerase I inhibitors in development    
or approved for the treatment of breast cancer
Time Course of Diarrhea and Neutropenia







Diarrhea (≥ Grade 3)
Cycle 1 and/or 2
Cycle 3 and/or 4
Cycle 4+
Onset, median days (range) [# cycle]











Neutropenia (≥ Grade 3)
Cycle 1 and/or 2
Cycle 3 and/or 4
Cycle 4+
Onset, median days (range) [# cycle]











41Source: Data as of 09May2011
Anti-diarrheals given therapeutically; no prophylactic anti-diarrheals administered
BEACON Phase 3 Registration Study of 
NKTR-102 in Metastatic Breast Cancer
42
Global enrollment completed ahead of schedule in August 2013;
Topline data expected end of 2014 or early 2015
Single Agent Chemotherapy
Outcomes in Refractory MBC
43
A = Adriamycin T = Taxane C = Capecitabine
Author Agent




JCO 2007 Ixabepilone x x x 11% 3.1
Cortes
JCO 2010 Eribulin x x x 9% 2.6
Cortes





(q14d + q21d) x x x / ‒ 29% 4.7
NKTR-102
(q21d only) x x x / ‒ 29% 5.6




•Etirinotecan pegol (NKTR-102) 
